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GENETIC COUNSELOR UTILIZATION AND INTERPRETATION OF SOMATIC
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Advisory Professor: Maureen Mork, M.S.

Lynch syndrome (LS) is a hereditary cancer predisposition syndrome characterized by increased risk
for colorectal and uterine cancers. Individuals with pathogenic variants in the mismatch repair
(MMR) genes (MLH1, MSH2/EPCAM, MSH6, PMS2) are diagnosed with LS and subsequently
recommended to proceed with high risk screening protocols to increase prevention and early detection
of LS-related cancers. Various tumor studies can help identify those at high risk for LS, but
sometimes create uncertainty with discordant screening and germline results, leading to unexplained
mismatch repair deficiency (UMMRD). Somatic testing of the MMR genes has created opportunities
for resolving UMMRD, thus clarifying LS status and ensuring appropriate cancer surveillance.
However, guidelines for such testing are currently limited. The purpose of this study was to examine
current and hypothetical ordering practices of cancer genetic counselors for LS evaluation and to
investigate participants’ interpretation of somatic MMR testing results. Two-hundred eligible
participants were recruited through the National Society of Genetic Counselors listserv and answered
questions regarding demographics, ordering practices, barriers to somatic MMR testing, theoretical
patient scenarios, and need for further guidelines. Statistical analysis was done using Chi-square,
Fisher exact, and Wilcoxon rank-sum tests while themes were identified from free-text responses.
Most respondents did not include somatic MMR testing in the work-up for LS and did not routinely
order this testing, but indicated interest in ordering this in conjunction with germline testing. The gap
between preferred testing strategies and current ordering practices for somatic MMR testing may be
due to reported laboratory and insurance-related barriers, particularly cost and coordination of tissue
specimens. Nearly all individuals endorsed the need for additional guidelines for somatic MMR
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testing, which could provide support to reduce barriers, encourage insurance coverage, and allow for
appropriate screening recommendations for patients and family members of those with UMMRD.
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INTRODUCTION
Lynch syndrome (LS), formerly known as hereditary nonpolyposis colorectal cancer (HNPCC),
is one of the most prevalent and well-defined hereditary cancer syndromes (Lynch et al., 2015). It is
caused by germline heterozygous pathogenic variants in the mismatch repair (MMR) genes (MSH2,
MSH6, MLH1, and PMS2), as well as EPCAM. (Lynch et al., 2015; Tiwari et al., 2016; Pena-Diaz et al.,
2015). Individuals with LS have an increased lifetime risk for colorectal and uterine cancers as well as
extracolonic cancers of the ovary, renal pelvis, stomach, small bowel, brain, and sebaceous gland
compared to the general population (Lynch et al., 2015; Tiwari et al., 2016; Vasen et al., 1999).
Individuals with LS tend to have an earlier age of diagnosis and a higher rate of multiple primary cancers
than the general population (Lynch et al., 2015; Tiwari et al., 2016; Vasen et al., 1999).
Microsatellite instability (MSI) analysis and immunohistochemistry (IHC) staining are often
initial tumor screens used to identify individuals at increased risk for LS (Battaglin et al., 2018; Cohen et
al., 2014; Tiwari et al., 2016). MSI analysis determines the mutation status of microsatellite repeats and
those with more mutated sequences are deemed MSI-high, which can be an indication of MMR
deficiency (Lynch et al., 2015; Pena-Diaz et al., 2015; Tiwari et al., 2016). IHC staining can be used to
determine MMR protein status in the tumor; absence of staining in one or more of these proteins raises
suspicion for a germline pathogenic variant in one of the MMR genes (Lynch et al., 2015; Pritchard, et
al., 2012). MLH1 promoter hypermethylation and/or BRAF somatic mutation analyses also contribute to
risk assessment as the presence of either MLH1 promoter hypermethylation or theV600E mutation in
BRAF are associated with sporadic MSI-high tumors as opposed to LS (Deng et al., 2004; McGivern et
al., 2004).
In addition to MLH1 promoter hypermethylation and BRAF V600E mutations, biallelic (or
“double”) somatic MMR mutations can also be responsible for some MMR deficient cancers in the
absence of a germline mutation, also known as unexplained mismatch repair deficiency (UMMRD)
(Mesenkamp et al., 2014; Sourrouille et al., 2012). UMMRD can be due to undetectable germline
pathogenic variants and large rearrangements, somatic mosaicism, false-positive staining, or biallelic
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somatic mutations (Haraldsdottir et al., 2014). Individuals with biallelic somatic mutations are
considered unlikely to have LS because these cases are either caused by two somatic mutations or one
somatic mutation combined with somatic loss of heterozygosity, thus resulting in MMR deficiency in the
tumor (Buecher et al., 2018; Mesenkamp et al., 2014).Biallelic somatic MMR mutations may explain up
to 52% of UMMRD, helping to inform LS status and potentially sparing patients and their families from
intensive cancer screenings (Mensenkamp et al., 2014; Sourrouille et al., 2012).
Biallelic somatic MMR mutations cannot be differentiated from LS using tumor pathology, MSI
analysis, or IHC staining, so challenges arise when UMMRD occurs (Haraldsdottir et al., 2014;
Hemminger et al., 2018). However, next-generation sequencing has led to more frequent utilization of
tumor profiling to pinpoint somatic mutations (Hamepl et al., 2018; Pritchard et al., 2012; Varga et al.,
2015) and can be applied to LS tumors as an additional risk assessment tool.
Even though there are opportunities to utilize somatic testing in the evaluation of LS, the
corresponding guidelines have not caught up to the available technology. There is currently no consensus
about the LS status of individuals with UMMRD (Batte, et al, 2013) and, somatic MMR testing does not
explain all MSI-high tumors without a germline mutation. This creates dilemmas for genetic counselors
and physicians in providing screening recommendations. Only 5.2% of genetic counselors have reported
being “completely prepared” and 67% reported being “somewhat prepared” to handle comprehensive
tumor profiling results (Goedde et al., 2017). However, it is still unknown how this applies to LS somatic
MMR testing. The National Comprehensive Cancer Network (NCCN) current guidelines (NCCN,
Version 1.2018) contain limited recommendations for the interpretation of somatic MMR testing for LS
in a footnote (LS-A 4 of 5; footnote d). The footnote discusses biallelic somatic MMR mutations as a
possible explanation for UMMRD and suggests genetic consultation for complex results without
guidelines for interpreting complex results. This minimal guidance leaves room for inconsistency among
genetic counseling practices.
The availability of somatic MMR testing in evaluation of LS has great implications for patient
management, but its use among cancer genetic counselors has not been studied. Thus, we aimed to
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investigate current somatic MMR ordering practices, and consistency in risk assessments by cancer
genetic counselors to identify gaps in available recommendations and assess the need for more
comprehensive guidelines.

METHODS
This study was approved by the University of Texas Health Science Center Institutional Review Board,
governed by the Committee for the Protection of Human Subjects (HSC-MS-18-0442).

Participants and Procedures:
Participants were recruited to this cross-sectional study through the National Society of Genetic
Counselors (NSGC) listserv between September 2018 and November 2018. A survey link was sent via
email to all NSGC registered members, followed by a reminder, and posted to the Cancer Special Interest
Group (SIG) discussion board. Practicing board-certified or board-eligible clinical genetic counselors,
who actively see patients in the cancer setting, were eligible to participate in the study. The survey was
anonymous and remained open for 8 weeks. Informed consent was obtained prior to proceeding to the
questionnaire portion of the survey. Participants were excluded from the study if they were employed by
a diagnostic laboratory, did not meet the eligibility criteria, or only completed the demographic section
of the survey.

Instrumentation:
Qualtrics (Qualtrics, Provo, UT) was used to administer the survey and collect data. Participants
who consented to the study were asked eligibility criteria, demographic information, current ordering
practices, scenarios involving hypothetical patients, and views on further guidelines. The subjects were
given an opportunity for free-text comments at the end of the survey. The question format varied, with
the vast majority (45/53 content questions) being multiple choice. Subjects could exit the survey at any
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point, and subjects were not required to answer every question. The study questionnaire was created by
the authors and was not externally validated (Appendix A).

Data Analysis:
Data was analyzed using STATA (version 13.1, College Station, TX) with a level of significance
of p≤0.05. Descriptive statistics were completed including medians for continuous variables and
frequencies and percentages for categorical variables. Demographic responses were compared to the
results of the NSGC 2018 Professional Status Survey (PSS) using proportion tests. Chi-square, Fisher
exact, and Wilcoxon rank-sum tests were used to compare differences between responses for selected
questions and estimate the significance. Free responses were analyzed to identify themes within
participant comments, with the flexibility to code multiple themes for one response.

RESULTS
Demographics:
Following the survey closure, there were 224 total responses. Thirteen responses were excluded
due to ineligibility, while 11 did not meet the minimum completeness requirement and were also
excluded. The remaining 200 respondents were included in the study. Since participants were not
required to answer every question, the total number of responses varied across questions. Demographic
information is reported in Table 1. The majority of participants worked full-time (98%, n = 195/200),
had less than six years of experience in a cancer setting (75%, n = 150/200), and did not practice
additional specialties (69%, n = 137/200). Most individuals (86%, n = 171/200) worked with other
genetic counselors. Just over half (52%, n = 103/198) of respondents practiced in a state with licensure.
The median number of colorectal cancer cases assessed per month (personal or family history) was five
(Interquartile range: 4-10) and the median number of uterine cancer cases assessed per month (personal
or family history) was three (Interquartile range: 2-5). Demographics were compared to the 2018 NSGC
PSS and did not reveal any statistically significant differences for licensure status or regions 1-5. Region
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6 was underrepresented in our responses compared to the PSS. While different work setting options were
presented in the two surveys, there were no statistically significant differences for the proportion of
individuals at a university medical center or in a private medical facility. However, there were a higher
proportion of genetic counselors who worked at a public medical facility in our cohort compared to the
PSS.

Table 1. Participant demographics
Academic Setting
All (n=200)
n (%)
Experience in Cancer
0-5 years
6-10 years
11-15 years
16-20 years
>20 years
Position Type
Full-time (>30 hr/wk)
Part-time (<30 hr/wk)
Setting *
Public
Private
University
Physician’s practice
Other
Additional Specialties
Only cancer cases
Other specialties*
General genetics
Pediatrics
Adult
Cardiology
Neurogenetics
Metabolic
Prenatal
Other
Cancer Subspecialty
None
Subspecialty *
Breast
Gynecological
Gastrointestinal
Genitourinary
Pediatric

Yes
(n=110)

No
(n=90)

84 (42)
15 (7.5)
6 (3)
4 (2)
1 (0.5)

66 (33)
13 (6.5)
3 (1.5)
4 (2)
4 (2)

Sole GC
pvalue

Yes
(n=29)

No
(n=171)

20 (10)
6 (3)
1 (0.5)
1 (0.5)
1 (0.5)

130
22 (11)
8 (4)
7 (3.5)
4 (2)

0.562
150 (75)
28 (14)
9 (4.5)
8 (4)
5 (2.5)

0.697

0.176
195 (97.5)
5 (2.5)

109 (54.5)
1 (0.5)

86 (43)
4 (2)

70 (35)
53 (26.5)
83 (41.5)
4 (2)
5 (2.5)

28 (14)
13 (6.5)
81 (40.5)
0 (0)
1 (0.5)

42 (21)
40 (20)
2 (1)
4 (2)
4 (2)

137 (68.5)

78 (39)

31 (15.5)
27 (13.5)
37 (18.5)
22 (11)
11 (5.5)
3 (1.5)
23 (11.5)
7 (3.5)
184 (92)
16 (8)
5 (2.5)
5 (2.5)
9 (4.5)
2 (1)
3 (1.5)

pvalue

0.154
27 (13.5)
2 (1)

168 (84)
3 (1.5)

0.002
<0.001
<0.001
0.040
0.176

17 (8.5)
10 (5)
0 (0)
2 (1)
0 (0)

53 (26.5)
43 (21.5)
83 (41.5)
2 (1)
5 (2.5)

0.004
0.292
<0.001
0.101
1.000

59 (29.5)

0.417

22 (11)

115 (57.5)

0.356

20 (10)
16 (8)
19 (9.5)
8 (4)
3 (1.5)
2 (1)
7 (3.5)
4 (2)

11 (5.5)
11 (5.5)
18 (9)
14 (7)
8 (4)
1 (0.5)
16 (8)
3 (1.5)

0.247
0.632
0.621
0.063
0.068
1.000
0.012
1.000

3 (1.5)
2 (1)
2 (1)
2 (1)
1 (0.5)
0 (0)
3 (1.5)
1 (0.5)

28 (14)
25 (12.5)
35 (17.5)
20 (10)
10 (5)
3 (1.5)
20 (10)
6 (3)

0.581
0.381
0.118
0.747
1.000
1.000
1.000
1.000

97 (48.5)

87 (43.5)

0.035

27

157

1.000

4 (2)
3 (1.5)
7 (3.5)
1 (0.5)
2 (1)

1 (0.5)
2 (1)
2 (1)
1 (0.5)
1 (0.5)

0.381
1.000
0.190
1.000
1.000

1 (0.5)
2 (1)
2 (1)
1 (0.5)
0 (0)

4 (2)
3 (1.5)
7 (3.5)
1 (0.5)
3 (1.5)

0.547
0.154
0.621
0.27
1.000
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Other
NSGC Region **
Region 1
Region 2
Region 3
Region 4
Region 5
Region 6
*
**

3 (1.5)

3 (1.5)

0 (0)

16 (8)
48 (24)
21 (11)
62 (31)
32 (16)
20 (10)

14 (7)
24 (12)
10 (5)
34 (17)
19 (9.5)
9 (4.5)

2 (1)
24 (12)
11 (5.5)
28 (14)
13 (6.5)
11 (5.5)

0.254
0.099

0 (0)

3 (1.5)

0 (0)
9 (4.5)
3 (1.5)
12 (6)
3 (1.5)
2 (1)

16 (8)
39 (19.5)
19 (9.5)
50 (25)
29 (14.5)
18 (9)

1.000
0.338

Subcategories are not mutually exclusive
Region 1 (CT, MA, ME, NH, RI, VT, CN Maritime Provinces)
Region 2 (DC, DE, MD, NJ, NY, PA, VA, WV, PR, VI Quebec)
Region 3 (AL, FL, GA, KY, LA, MS, NC, SC, TN)
Region 4 (AR, IA, IL, IN, KS, MI, MN, MO, ND, NE, OH, OK, SD, WI, Ontario)
Region 5 (AZ, CO, MT, NM, TX, UT, WY, Alberta, Manitoba, Sask)
Region 6 (AK, CA, HI, ID, NV, OR, WA, British Columbia)

Ordering Practices:
Participants were asked about their institution’s ordering practices for IHC, MSI, and somatic
MMR testing in the work-up for LS. These responses are reported in Table 2. Most individuals (91%, n =
181/200) reported their institution included IHC and the majority of those (85%, n = 154/181) used an
in-house laboratory. Less than half (44%, n = 87/199) worked at an institution that included MSI in the
LS work-up, with the majority of these (74%, n = 64/87) performed at an in-house laboratory. Genetic
counselors who worked in an academic setting were more likely to have an institution that used an inhouse laboratory for both IHC (p = 0.003) and MSI (p < 0.0001) testing than those not at an academic
institution. Less than a third (29%, n = 57/199) of respondents reported their institution included somatic
MMR testing in evaluation of LS, with the majority (66%, n = 37/56) performed at an external
laboratory. Of those who had experience ordering somatic MMR testing, less than a quarter (23%, n =
28/124) reported “routinely” ordering this testing and half (50%, n = 62/124) reported only using this
testing “occasionally” or “rarely”.
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Table 2. Description of ordering practices
All
(n=200)
n (%)
IHC work-up
Included
Not included
Unsure
IHC testing^
In-house
Send-out
Unsure
MSI work-up
Included
Not included
Unsure
MSI testing^
In-house
Send-out
Unsure
MMR work-up
Included
Not included
Unsure
MMR testing^
In-house
Send-out
Unsure
Tumor Profiling
Experience
Yes
No
Tumor Profiling Comfort
Extremely comf.
Somewhat comf.
Neutral
Somewhat uncomf.
Extremely uncomf.
Somatic MMR experience
Yes
No
Somatic MMR comfort
Extremely comf.
Somewhat comf.
Neutral
Somewhat uncomf.
Extremely uncomf.
MMR impacts assessment
Always
Usually
Sometimes
Rarely
Never
Experience/perceive
barriers
Yes

Academic Setting
Yes
(n=110)

No
(n=90)

pvalue

Sole GC
Yes
(n=29)

No (n=171)

27 (14)
2 (1)
0 (0)

154 (77)
12 (6)
5 (2)

24 (13)
3 (2)
0 (0)

130 (72)
13 (7)
10 (6)

12 (6)
16 (8)
1 (1)

75 (37)
83 (42)
12 (6)

3 (3)
7 (8)
2 (2)

61 (70)
10 (12)
4 (5)

7 (3)
21 (11)
1 (1)

50 (25)
106 (53)
14 (7)

1 (2)
6 (11)
0 (0)

14 (25)
31 (55)
4 (7)

20 (10)
9 (4)

145 (72)
24 (12)

2 (1)
8 (4)
9 (5)
7 (4)
3 (2)

20 (10)
92 (46)
22 (11)
31 (15)
3 (2)

22 (11)
7 (4)

139 (70)
30 (15)

8 (6)
11 (8)
3 (2)
6 (4)
1 (1)

65 (45)
30 (21)
12 (8)
6 (4)
1 (1)

4 (3)
7 (4)
9 (6)
1 (1)
0 (0)

42 (26)
64 (40)
20 (12)
9 (6)
3 (2)

17 (9)

132 (68)

0.634
181 (91)
14 (7)
5 (2)

101 (51)
6 (3)
3 (1)

80 (40)
8 (4)
2 (1)

154 (86)
16 (9)
10 (5)

93 (52)
3 (2)
4 (2)

61 (34)
13 (7)
6 (3)

87 (44)
99 (50)
13 (6)

54 (27)
49 (25)
6 (3)

33 (17)
50 (25)
7 (3)

64 (74)
17 (19)
6 (7)

49 (56)
3 (4)
2 (2)

15 (17)
14 (16)
4 (5)

57 (29)
127 (64)
15 (7)

32 (16)
68 (34)
9 (4)

25 (13)
59 (30)
6 (3)

15 (27)
37 (66)
4 (7)

12 (21)
18 (32)
2 (4)

3 (5)
19 (34)
2 (4)

165 (83)
33 (17)

91 (46)
18 (9)

74 (37)
15 (8)

22 (11)
100 (51)
31 (16)
38 (19)
6 (3)

14 (7)
57 (29)
16 (8)
19 (9.5)
2 (1)

8 (4)
43 (22)
15 (8)
19 (9.5)
4 (2)

161 (81)
37 (19)

91 (46)
18 (9)

70 (35)
19 (10)

73 (37)
93 (48)
15 (8)
12 (6)
2 (1)

44 (23)
53 (27)
6 (3)
4 (2)
0 (0)

29 (15)
40 (20)
9 (5)
8 (4)
2 (1)

46 (29)
71 (45)
29 (18)
10 (6)
3 (2)

29 (18)
44 (28)
10 (6)
5 (3)
3 (2)

17 (11)
27 (17)
19 (12)
5 (3)
0 (0)

149 (77)

84 (43)

65 (34)

pvalue
0.646

0.003

0.433

0.185

0.770

<0.001

<0.001

0.867

0.584

0.116

0.803

0.949

0.025

0.659

0.004

0.385

0.415

0.134

0.007

0.041

0.069

0.534

0.029
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No
45 (23)
23 (12)
22 (11)
Barriers**
Cost
102 (51)
60 (30)
42 (21)
Coordinating tissue
99 (50)
52 (26)
47 (24)
Lack of institution support
35 (18)
19 (10)
16 (8)
Unsure how to interpret
12 (6)
7 (4)
5 (3)
Lack of time
17 (9)
12 (6)
5 (3)
Not available in-house
46 (23)
32 (16)
14 (7)
Not offered by preferred
lab
38 (19)
26 (13)
12 (6)
Other
34 (17)
20 (10)
14 (7)
Insurance/billing issues*
9 (5)
6 (3)
3 (2)
Limited tissue*
6 (3)
4(2)
2(1)
Turnaround time*
7 (4)
3 (2)
4 (2)
*
Themes from text responses
^ Only includes 'yes' responses from previous category
** Subcategories not mutually exclusive

11 (5)

34 (18)

15 (8)
10 (5)
7 (4)
2 (1)
3 (2)
8 (4)

87 (44)
89 (45)
28 (14)
10 (5)
14 (7)
38 (19)

0.933
0.080
0.309
0.687
0.718
0.633

0.065
6 (3)
32 (16)
0.579
2 (1)
32 (16)
0.518
0(0)
9(5)
0.692
0(0)
6(3)
0.703
0 (0)
7(4)
Uncomf. = uncomfortable
Comf. = comfortable

0.800
0.298
0.362
0.596
0.596

0.267
0.486
0.925
0.811
0.177
0.024

The survey also investigated genetic counselor experience and comfort level with both tumor
profiling and somatic MMR testing. Most individuals (83%, n = 165/198) had experience with tumor
profiling results (such as those obtained from external vendors such as FoundationOne) and the majority
(62%, n = 122/197) reported they felt “somewhat comfortable” or “extremely comfortable” interpreting
these types of results. The majority of respondents (81%, n = 161/198) had experience reviewing somatic
MMR testing results, with nearly three-quarters (73%, n = 117/159) of those results “usually
contributing” or “always contributing” to the risk assessment of LS cases. When participants were asked
if they do or would feel comfortable interpreting somatic MMR results, 85% (n = 166/195) reported they
felt “somewhat comfortable” or “extremely comfortable”.
Over three-quarters (76.8%, n = 149/194) of respondents experienced or perceived barriers to
ordering somatic MMR testing, with cost and coordinating tissue samples being the most frequently
cited. The reported barriers are summarized in Figure 1. Genetic counselors at an academic institution
were more likely (p = 0.024) to cite lack of in-house availability as a barrier to somatic MMR testing
compared to those not at an academic institution. Those who work with other cancer genetic counselors
were more likely to experience or perceive barriers to somatic MMR testing than those who were the
sole cancer genetic counselor at their institution (p = 0.029).
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Figure 1. Perceived barriers by participants to somatic MMR testing
Not Offered by Preferred Lab

19%

Not Available In-house

23%

Lack of Time

9%

Unsure of Interpretation

6%

Lack of Institution Support

18%

Coordinating Tissue

50%

Cost

51%

Other

6% 5%

0%
Other

4% 3%

10%

Insurance/billing^

20%

30%

Turnaround time^

40%

50%

60%

Limited tissue^

*Categories not mutually exclusive ^Themes coded from free-text responses

Scenario-based Questions:
During the scenario portion of the survey, participants were given four different theoretical
scenarios created by the authors with information about a hypothetical patient’s diagnosis and tumor
staining results in addition to a pedigree. Question topics included the likelihood of the patient having LS
(before and after learning the patient’s somatic MMR results), the next recommended step in the genetics
evaluation, and screening recommendations for the patient and first-degree relatives. The pedigrees for
these scenarios are displayed in Figure 2.
Scenario 1 (Figure 2: A) involved a 67-year old male with colorectal cancer that had loss of
staining in MLH1 and PMS2 with negative MLH1 promoter methylation and BRAF mutation analysis.
This patient was later revealed to have biallelic somatic mutations in MLH1 with negative germline
testing. Scenario 2 (Figure 2: B) was a 23-year old female with colorectal cancer and a noncontributory
family history. Tumor testing showed loss of staining in MSH2 and MSH6. Somatic testing showed
biallelic somatic mutations in MSH2 and germline testing was negative. Scenario 3 (Figure 2: C) showed
a 46-year old female with uterine cancer and family history meeting Amsterdam criteria. The tumor IHC
results were loss of staining in MSH2 and MSH6. Participants were later informed her somatic testing
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showed a monoallelic mutation in MSH2 with negative germline testing. Scenario 4 (Figure 2: D)
involved a 62-year old male with colorectal cancer and loss of staining in MLH1 and PMS2 with
negative MLH1 promoter methylation and BRAF mutation analysis. His family history was
noncontributory, although his unaffected father died at age 52. Both the somatic and germline testing
results were negative.
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A

B

C

D

Figure 2. Scenario pedigrees (A-D) provided to participants.
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For all scenarios, the majority (52-59%) of participants indicated their next step would have been
concurrent germline and somatic testing that included the MMR genes. For the scenarios involving
biallelic somatic mutations, the initial likelihood for LS was mostly ranked as “unlikely” (scenario 1;
79%, n = 152/192) or “highly likely” (scenario 2; 82%, n = 155/190). After learning the somatic testing
results for these scenarios, the majority (77%, n = 148/192; 89%, n = 169/190 for scenario 1 and 2,
respectively) of respondents shifted to a lower LS likelihood of either “unlikely” or “definitely not”. For
the scenario regarding monoallelic somatic mutations (scenario 3), most participants indicated “highly
likely” before (88%, n = 165/187) and after (75%, n = 139/186) knowing the patient’s somatic results,
with most (71%, n = 133/186) individuals selecting the same likelihood for both questions. Scenario 4
involved a patient with negative somatic and germline results, with most (59%, n = 105/177) individuals
ranking the likelihood for LS as “unlikely” for both risk assessment questions and approximately a
quarter (28%, n = 50/177) downgrading their LS suspicion. Most individuals recommended LS screening
for the patient (81%, n = 149/185) with monoallelic somatic mutations (scenario 3) and her first-degree
relatives (68%, n = 128/187). For the other three scenarios, the majority screening recommendation was
“population-level” for the proband (48-66%) and “early colonoscopy based on family history” for the
first-degree relatives (56-90%). The scenario responses are summarized in Table 3.
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Table 3. Participant responses to scenario questions

Patient

Pedigree
Somatic Results

Scenario 1
67-year old male
(colorectal cx).
Loss of
MLH1/PMS2**.
Neg family hx.
B

Scenario 2
23-year old
female (colorectal
cx). Loss of
MSH2/MSH6.
Neg family hx.
C

*Biallelic MLH1
somatic mut.
Germline neg.

*Biallelic MSH2
somatic mut.
Germline neg.

n (%)
n (%)
Q1. Lynch Likelihood
Absolutely
0 (0)
0 (0)
Highly likely
40 (21)
155 (82)
Unlikely
152 (79)
35 (18)
Definitely not
0 (0)
0 (0)
Q2. Next step
Germline
52 (27)
48 (25)
Germline reflex somatic
19 (10)
35 (18)
Germline + somatic
114 (59)
102 (54)
No further eval.
3 (2)
0 (0)
Other
4 (2)
5 (3)
Q3. *Lynch likelihood
Absolutely
0 (0)
1 (1)
Highly likely
3 (2)
4 (2)
Unlikely
60 (31)
107 (56)
Definitely not
129 (67)
78 (41)
Q4. Proband screening
Population
127 (66)
90 (48)
Lynch
6 (3)
13 (7)
Other
59 (31)
86 (45)
Personal hx
42 (22)
56 (30)
Q5. FDR screening
Population
56 (29)
5 (3)
Family hx
122 (64)
172 (90)
Lynch
0 (0)
3 (2)
Other
13 (7)
10 (5)
Key
*
Somatic test results provided after Q2
**
Negative MLH1 methylation and BRAF mutation analysis

Scenario 3
46-year old female
(uterine cx). Loss
of MSH2/MSH6.
Meets Amsterdam.
D
*Monoallelic
MSH2 somatic
mut. Germline
neg.
n (%)

Scenario 4
62-year old male
(colorectal cx).
Loss of
MLH1/PMS2**.
Neg family hx.
E
*Somatic &
germline
negative.
n (%)

20 (11)
165 (88)
2 (1)
0 (0)

0 (0)
25 (14)
151 (85)
2 (1)

56 (30)
32 (17)
98 (52)
0 (0)
1 (1)

43 (24)
18 (10)
106 (59)
8 (5)
4 (2)

9 (5)
139 (75)
35 (19)
3 (1)

0 (0)
13 (7)
121 (68)
44 (25)

10 (5)
149 (81)
26 (14)
14 (8)

105 (59)
18 (10)
54 (31)
26 (15)

0 (0)
45 (24)
128 (68)
14 (8)

52 (29)
100 (56)
12 (7)
14 (8)

Further Guidelines and Comments:
When asked if additional, more specific, national guidelines for the ordering and/or
interpretation of MMR somatic testing would be beneficial, 77% (n=140) of respondents answered ‘yes’
and 17% (n=31) responded ‘maybe’.
At the conclusion of the survey, participants were given an opportunity to provide additional
comments in a free-text format. Select comments are displayed in Table 4. While extensive patterns in
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the comment section did not emerge, a few individuals confirmed further guidelines would be helpful. A
few others also reiterated that in their experiences, concurrent germline and somatic testing was
beneficial for billing purposes. None of the comments provided explanations for individuals who
indicated they did not feel further guidelines would be helpful.

Table 4. Free response examples

Theme

Example Comment

Barriers to
Somatic Testing

“While we may want to start with germline and then reflex to somatic (in
some cases)… there is better coverage to order concurrently; so while it
may not clinically be the best way to order testing, it is financially better for
our patients.”
“Turnaround time is also a contributing factor… I would sacrifice somatic
results for germline results in those cases where surgical decision making
regarding Lynch syndrome are reliant upon results...”

Further
Guidelines

“Our clinic is getting more and more questions from oncologists at our
institution regarding tumor testing for Lynch and other conditions. National
guidelines for tumor testing in general would be extremely beneficial for
cancer genetic counseling.”
“Additional information on interpretation of MMR somatic tumor testing
would be extremely beneficial. A lot has been learning as I go and I am not
sure I am doing that great of a job at it…”

Screening
Recommendations

“We make guideline recommendations based on the NCCN guidelines. In
some situations, we may encourage more high risk screening methods…
but we defer to the patient's supervising physician…”
“For those with abnormal results and no informative germline/somatic
results there is no clear cut recommendations and every family needs to be
looked at individual and notes should include limitations to our knowledge
and any recommendations.”
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DISCUSSION
Cancer genetic counselors currently have several tools available to assess an individual’s risk of
LS, including IHC staining, MSI analysis, somatic MMR testing, and germline testing. While not all of
these tools may be indicated in every case, UMMRD cases may require more extensive testing to
accurately determine LS status and ultimately screening recommendations for patients and their relatives.
Given the importance of appropriate patient management, this study surveyed two hundred currentlypracticing cancer genetic counselors regarding their current ordering practices and interpretation of
somatic MMR results in the context of a hypothetical LS case to evaluate the sufficiency of current
national guidelines. The results of this survey demonstrate cancer genetic counselors’ acknowledged
importance of somatic MMR testing in theoretical practice and in past instances, despite a scarcity of
routine inclusion in real-world ordering practices.
Cancer genetic counselors seem to be largely aware of the benefits of somatic MMR testing and
demonstrate interest in ordering it for their patients. Participants with past experience utilizing somatic
MMR testing indicated the positive impact these results had on risk assessment. This sentiment was also
reflected in the hypothetical scenarios, as a majority of participants indicated they would consider
somatic MMR testing in conjunction with germline testing as the ideal next step in their LS evaluation.
Previous literature has shown that patients also tend to positively view tumor screening for LS and
understand its benefits (Hunter et al., 2015).
Despite genetic counselor understanding of its benefits, somatic MMR testing was rarely
included in the respondents’ current institution ordering practices for LS work-up. While most
respondents had previous experience ordering somatic MMR testing and reported feeling at least
“somewhat comfortable” with interpreting these results, only a small minority reported routinely
ordering this testing. The discrepancy between ideal and current testing practices illustrates a gap,
perhaps related to barriers to testing.
In fact, a high frequency of genetic counselors reported encountering or perceiving barriers to
ordering somatic MMR testing. The most common reported barriers included cost, coordinating tissue
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samples, and lack of in-house availability, with lack of knowledge regarding result interpretation among
the least frequently cited. Many individuals reported additional barriers in the free-text response, with
themes emerging in billing/insurance issues, long turnaround time, and lack of tumor tissue. Since these
themes were individually reported as free-text responses and not displayed as options to all participants,
these barriers may be underrepresented in this study. Previous literature regarding ordering tumor
profiling found each of these three barriers to be reported in more than 70% of their participants
(Kurzrock et al., 2015), which may be similar in somatic MMR testing.
Interestingly, genetic counselors who were the sole genetic counselor at their institution were
less likely to report experiencing these barriers. This may be an indication that sole genetic counselors
are viewed to have slightly different scopes of practice or perhaps reflects a difference in clinic structure
or institution size.
The vast majority of participants reported that additional, more specific, national guidelines
surrounding somatic MMR testing would be beneficial to their practice. The NCCN current guidelines
(NCCN, Version 1.2018) includes limited recommendations for the interpretation of somatic MMR
testing in the form of a footnote (LS-A 4 of 5; footnote d). This footnote cites evidence supporting
biallelic somatic MMR mutations as an explanation for UMMRD, therefore tumor sequencing may assist
in clarifying the result. It discusses that in cases with monoallelic somatic mutations, the unidentified
mutation could be germline or somatic. However, the guidelines state family history-based management
should be used regardless of somatic testing results. The footnote also suggests genetic consultation for
complex results but doesn’t provide guidelines for interpreting those results. While there are mentions of
somatic MMR testing in national guidelines, it does not encompass all possible scenarios, and is not
nearly as extensive as guidelines for germline testing. The creation of clear guidelines may further
increase genetic counselor comfort with ordering somatic MMR testing and encourage them to seek out
this testing more often, thereby enhancing patient management. Since some insurance companies use
national guidelines to determine coverage criteria, this may also reduce insurance and billing issues.
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Study limitations:
This study population may reflect a self-selecting bias in which those genetic counselors with
experience or interest in somatic MMR testing may have been more likely to complete the survey than
those with more limited knowledge. In addition, the questionnaire was created by the authors and has not
been formally validated. While most participant characteristics were not significantly different between
this study and the PSS, including licensure and regions 1-5, this study may have had a higher proportion
of genetic counselors who worked at a public medical facility and a lower proportion of genetic
counselors in region 6, which could have created a skewed sample. However, the work setting
differences may simply be a reflection of different answer choices included on this survey compared to
those of the PSS. Additionally, the NCCN guidelines underwent revisions within a few months of survey
distribution which changed recommendations for those with monoallelic somatic mutations from LS
screening to family history-based screening. Therefore, individuals may have made recommendations for
LS screening as a reflection of prior guidelines.
Of note, for three of the scenario questions, it was observed that a majority of participants chose
“population-level screening” for a proband affected with cancer. However, individuals with a history of
cancer generally require additional screening compared to the general population in order to monitor for
disease recurrence. Therefore, this survey response may represent an artifact of the survey structure or
wording for this specific question. While the authors intended this to represent typical post-cancer
screening protocols, this phrase may have been interpreted differently by respondents. Given the only
other provided response was LS screening, this option may have been understood as non-LS screening or
as typical screening for the colon/uterine cancer population. Therefore, conclusions could not be drawn
regarding these responses.

Practice Implications:
This study provides insights into the ordering practices of cancer genetic counselors in
evaluating for LS, interpretations of somatic MMR testing, and barriers to this testing. Since many of the
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reported barriers involved lab-related issues rather than knowledge, it may be beneficial for genetic
counselors to advocate for different lab billing practices or in-house somatic MMR testing to ensure this
option is available, especially for UMMRD cases.
While many genetic counselors reported some level of comfort with interpreting somatic MMR
testing results, further guidelines may allow for further consensus, higher comfort levels, and portray
benefit to insurance companies. This may provide genetic counselors with more guideline resources,
confidence in their abilities to interpret somatic MMR testing, and leverage when advocating for this
testing option. Further guidelines may also reflect larger consensus and wider acceptance as a risk
assessment tool, which may aid in lowering costs and improving insurance coverage.

Research Recommendations:
Further studies investigating the barriers to somatic MMR testing may be beneficial in
determining strategies for eliminating or reducing those barriers. These potential studies could also
explore and confirm the differences between sole genetic counselors and those who work along with
other genetic counselors in terms of ordering practices, comfort with somatic testing, and likelihood to
report barriers to somatic MMR testing. Advancements in genetic knowledge and cancer technologies
may create other avenues for LS risk assessment or reveal other explanations for UMMRD, which may
alter ordering practices. Future research could compare ordering practices over time to find other factors
contributing to the rate of testing uptake and accessibility of new testing options.
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APPENDIX
Appendix A. Complete survey of this study
Start of Block: Consent
Q1 You are invited to take part in a research study called, “Genetic Counselor Utilization and
Interpretation of Somatic Tumor Testing for Lynch Syndrome”, conducted by Danielle Williams, of
The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical
Sciences.
The purpose of this study is to describe current clinical practice among genetic counselors seeing cancer
patients for evaluation of Lynch syndrome. All board-certified or board-eligible genetic counselors who
see cancer patients are invited to participate, regardless of exposure to somatic tumor testing.
If you consent to take part in this study you will complete a 15-20 minute survey via the online survey
tool, Qualtrics. All survey submissions will be anonymous.
The information you provide will help us better understand current clinical practices of cancer genetic
counselors evaluating patients for Lynch syndrome. You may not receive any direct benefit from taking
part in this study. The only possible risk may be breach of confidentiality; the information collected will
not contain identifying information. You have the alternative to choose to not take part in this study and
may withdraw at any time.
There is no cost and you will not be paid to take part in this study. You will not be personally identified
in any reports or publications that may result from this study. Any personal information about you that is
gathered during this study will remain confidential to every extent of the law.
This research project has been reviewed by the Committee for the Protection of Human Subjects (CPHS)
of the University of Texas Health Science Center at Houston (HSC-MS-18-0442). For any questions
about research subjects rights call CPHS at (713) 500-7943. This study is being conducted by M.S.
Candidate Danielle Williams under the direction of Maureen Mork, M.S., C.G.C. Should you have any
questions, please feel free to contact either at danielle.williams@uth.tmc.edu or
memork@mdanderson.org.
o I have read the consent and agree to take part in the study (1)
o I do not provide my consent and/or do not wish to take part in the study (2)
Skip To: End of Survey If You are invited to take part in a research study called, “Genetic Counselor
Utilization and Inter... = I do not provide my consent and/or do not wish to take part in the study
Start of Block: Qualification Questions
Q2 Are you a currently practicing, board certified or board eligible, genetic counselor who sees patients
for evaluation of hereditary cancer?
o Yes (1)
o No (2)
Skip To: End of Survey If Are you a currently practicing, board certified or board eligible, genetic
counselor who sees pat... = No
Q3 Do you work in a clinical or non-clinical setting?
o I am a clinical counselor and counsel patients as a regular part of my job (1)
o I am a non-clinical counselor and typically do not counsel patients (2)
Skip To: End of Survey If Do you work in a clinical or non-clinical setting? = I am a non-clinical
counselor and typically do not counsel patients
Start of Block: Demographics

19

Q4 For how many years have you been seeing patients for evaluation of hereditary cancer?
o 0-5 years (1)
o 6-10 years (2)
o 11-15 years (3)
o 16-20 years (4)
o 20+ years (5)
Q5 Do you work as a genetic counselor full-time or part-time?
o Part-time (1)
o Full-time (>30 hours per week) (2)
Q6 What type of setting do you work in? Select all that apply
▢ Public hospital/medical facility (1)
▢ Private hospital/medical facility (2)
▢ University Medical Center (3)
▢ Physician’s private practice (4)
▢ Diagnostic laboratory (5)
▢ Other (6) ________________________________________________
Display This Question: If What type of setting do you work in? Select all that apply = Diagnostic
laboratory
Q7 Does your employer offer somatic MMR testing? (Haraldsdottir et al., 2014; Mensenkamp et al.,
2014; NCCN, Version 3.2017)
o Yes (1)
o No (2)
Skip To: End of Survey If Does your employer offer somatic MMR testing?... = No
Q8 Do you consider your workplace to be an academic or non-academic institution?
o Academic (1)
o Non-academic (2)
Q9 Do you exclusively see cancer cases?
o Yes (1)
o No, I see other specialties as well (2)
Display This Question: If Do you exclusively see cancer cases? = No, I see other specialties as well
Q10 What other specialties do you see? Select all that apply
▢ General genetics (1)
▢ Pediatrics (2)
▢ Adult genetics (3)
▢ Cardiology (4)
▢ Neurogenetics (5)
▢ Metabolic diseases (6)
▢ Prenatal (7)
▢ Other (8) ________________________________________________
Q11 Do you specialize in a certain domain within the cancer setting?
o Yes (1)
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o

No, I practice in a general cancer genetics setting (2)

Display This Question: If Do you specialize in a certain domain within the cancer setting? = Yes
Q12 Which cancer domain do you specialize in? Select all that apply
▢ Breast (1)
▢ Gynecological (2)
▢ Gastrointestinal (GI) (3)
▢ Genitourinary (GU) (4)
▢ Endocrine (5)
▢ Dermatology (6)
▢ Pediatric (7)
▢ Other (8) ________________________________________________
Q13 Do you work with other cancer genetic counselors?
o Yes, I work with other cancer genetic counselors (1)
o No, I am the only cancer genetic counselor at my institution (2)
Q14 In which region do you currently practice?
o Region 1 (CT, MA, ME, NH, RI, VT, CN Maritime Provinces) (1)
o Region 2 (DC, DE, MD, NJ, NY, PA, VA, WV, PR, VI, Quebec) (2)
o Region 3 (AL, FL, GA, KY, LA, MS, NC, SC, TN) (3)
o Region 4 (AR, IA, IL, IN, KS, MI, MN, MO, ND, NE, OH, OK, SD, WI, Ontario) (4)
o Region 5 (AZ, CO, MT, NM, TX, UT, WY, Alberta, Manitoba, Sask) (5)
o Region 6 (AK, CA, HI, ID, NV, OR, WA, British Columbia) (6)
Q15 Does your state/province currently have licensure?
o Yes (1)
o No (2)
Start of Block: Current practices
Q16 About how many cases (personal or family history) do you see per month for colorectal cancer?
Q17 About how many cases (personal or family history) do you see per month for uterine cancer?
Q18 Does your institution include immunohistochemistry (IHC) tumor staining in the work-up for Lynch
syndrome?
o Yes (1)
o No (2)
o Unsure (3)
Display This Question: If Does your institution include immunohistochemistry (IHC) tumor staining in
the work-up for Lynch... = Yes
Q19 Is IHC testing performed in-house or through a send-out laboratory?
o In-house (1)
o Send-out (2)
o Unsure (3)
Q20 Does your institution include microsatellite instability (MSI) testing in the work-up for Lynch
syndrome?
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o
o
o

Yes (1)
No (2)
Unsure (3)

Display This Question: If Does your institution include microsatellite instability (MSI) testing in the
work-up for Lynch s... = Yes
Q21 Is MSI testing performed in-house or through a send-out laboratory?
o In-house (1)
o Send-out (2)
o Unsure (3)
Q22 Does your institution include somatic tumor testing of the mismatch repair (MMR) genes in the
work-up for Lynch syndrome? (Haraldsdottir et al., 2014; Mensenkamp et al., 2014; NCCN, Version
3.2017)
o Yes (1)
o No (2)
o Unsure (3)
Display This Question: If Does your institution include somatic tumor testing of the mismatch repair
(MMR) genes in the wor... = Yes
Q23 Is MMR somatic tumor testing performed in-house or through a send-out laboratory?
o In-house (1)
o Send-out (2)
o Unsure (3)
Q24 Do you have experience with tumor profiling testing results (FoundationOne)?
o Yes (1)
o No (2)
Q25 How comfortable do you feel interpreting tumor profiling results (FoundationOne)?
o Extremely comfortable (1)
o Somewhat comfortable (2)
o Neither comfortable nor uncomfortable (3)
o Somewhat uncomfortable (4)
o Extremely uncomfortable (5)
Q26 Have you ever ordered and/or coordinated somatic tumor testing of the MMR genes in evaluation of
Lynch syndrome?
o Yes (1)
o No (2)
Display This Question: If Have you ever ordered and/or coordinated somatic tumor testing of the MMR
genes in evaluation of... = Yes
Q27 Have you ever ordered and/or coordinated somatic testing of the MMR in evaluation of Lynch
syndrome for a colon tumor?
o Yes (1)
o No (2)
Display This Question: If Have you ever ordered and/or coordinated somatic tumor testing of the MMR
genes in evaluation of... = Yes
Q28 Have you ever ordered and/or coordinated somatic testing of the MMR genes in evaluation of
Lynch syndrome for a uterine tumor?
o Yes (1)
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o

No (2)

Display This Question: If Have you ever ordered and/or coordinated somatic tumor testing of the MMR
genes in evaluation of... = Yes
Q29 Is somatic MMR testing utilized when are evaluating a patient for Lynch syndrome?
o Rarely ( (1)
o Occasionally (10-30% of the time) (2)
o Often (30-80% of the time) (3)
o Routinely (>80% of the time) (4)
Q30 Have you ever reviewed/interpreted colon or uterine MMR somatic tumor testing results?
o Yes (1)
o No (2)
Display This Question: If Have you ever reviewed/interpreted colon or uterine MMR somatic tumor
testing results? = Yes
Q31 In the cases where you have reviewed/interpreted somatic MMR tumor testing results, did those
results contribute to your Lynch syndrome risk assessment?
o Always (100% of the time) (1)
o Usually (70-99% of the time) (2)
o Sometimes (30-70% of the time) (3)
o Rarely (1-30% of the time) (4)
o Never (0% of the time) (5)
Display This Question: If Have you ever reviewed/interpreted colon or uterine MMR somatic tumor
testing results? = No
Q32 What are the reasons that contribute to not reviewing/interpreting colon or uterine MMR somatic
tumor testing results? Select all that apply
▢ I don’t feel comfortable interpreting somatic tumor testing results (1)
▢ I have not received training for interpreting somatic tumor testing results (2)
▢ The results wouldn’t contribute to my risk assessment (3)
▢ My institution doesn’t order somatic testing (4)
▢ We have other providers to do this (5)
▢ I don’t have time to review the results (6)
▢ My institution does not consider this part of the genetic counseling scope (7)
▢ Other (8) ________________________________________________
Q33 Have you experienced or perceive any barriers to ordering somatic MMR testing?
o Yes (1)
o No (2)
Q34 What are the barriers you have experienced or perceive? Select all that apply
▢ Cost (1)
▢ Coordinating tissue samples (2)
▢ Lack of institution support (3)
▢ Unsure how to interpret the results (4)
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▢ Lack of time (5)
▢ Not available in-house (6)
▢ Not offered by preferred genetic testing lab(s) (7)
▢ Other (8) ________________________________________________
Q35 Do/would you feel comfortable interpreting colon and/or uterine MMR somatic tumor testing
results and including them in your risk assessment?
o Extremely comfortable (1)
o Somewhat comfortable (2)
o Neither comfortable nor uncomfortable (3)
o Somewhat uncomfortable (4)
o Extremely uncomfortable (5)
Start of Block: Scenario 1
Q36 The following questions refer to the scenario below:
Mr. Smith is a 67-year old male recently diagnosed with colorectal cancer. Tumor testing revealed loss
of staining in MLH1 and PMS2. MLH1 promoter methylation and BRAF mutation analysis were both
negative. The patient's family history is below:

Q38 What would you perceive this patient’s chance of having Lynch syndrome to be?
o This patient absolutely has Lynch syndrome (1)
o It’s highly likely this patient has Lynch syndrome (2)
o It’s unlikely this patient has Lynch syndrome (3)
o This patient definitely does not have Lynch syndrome (4)
Q39 What would be your next step in evaluating this patient for Lynch syndrome?
o Germline testing to include MMR genes (1)
o Germline testing to include MMR genes with reflex to somatic MMR testing if negative (2)
o Concurrent germline testing to include MMR genes plus somatic MMR testing (3)
o No further evaluation (4)
o Other (5) ________________________________________________
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Q40 Somatic MMR testing reveals biallelic somatic mutations in MLH1. Germline testing for MMR
genes was negative. Given this additional information, what do you perceive this patient’s chance of
having Lynch syndrome to be?
o This patient absolutely has Lynch syndrome (1)
o It’s highly likely this patient has Lynch syndrome (2)
o It’s unlikely this patient has Lynch syndrome (3)
o This patient definitely does not have Lynch syndrome (4)
Q41 What screening recommendations would you give this patient?
o Population-level screening (1)
o Lynch syndrome screening (2)
o Other (3) ________________________________________________
Q42 What screening recommendations would you give this patient’s first-degree relatives?
o Population-level screening (1)
o Earlier colonoscopy based on family history (2)
o Lynch syndrome screening (3)
o Other (4) ________________________________________________
Start of Block: Scenario 2
Q43 The following questions refer to the scenario below:
Ms. Jones is a 23-year old female recently diagnosed with colorectal cancer. Tumor testing revealed loss
of staining in MSH2 and MSH6. The patient’s family history is below:

Q44 What would you perceive this patient’s chance of having Lynch syndrome to be?
o This patient absolutely has Lynch syndrome (1)
o It’s highly likely this patient has Lynch syndrome (2)
o It’s unlikely this patient has Lynch syndrome (3)
o This patient definitely does not have Lynch syndrome (4)
Q45 What would be your next step in evaluating this patient for Lynch syndrome?
o Germline testing to include MMR genes (1)
o Germline testing to include MMR genes with reflex to somatic MMR testing if negative (2)
o Concurrent germline testing to include MMR genes plus somatic MMR testing (3)
o No further evaluation (4)
o Other (5) ________________________________________________
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Q46 Somatic MMR testing reveals biallelic somatic mutations in MSH2. Germline testing for MMR
genes was negative. Given this additional information, what do you perceive this patient’s chance of
having Lynch syndrome to be?
o This patient absolutely has Lynch syndrome (1)
o It’s highly likely this patient has Lynch syndrome (2)
o It’s unlikely this patient has Lynch syndrome (3)
o This patient definitely does not have Lynch syndrome (4)
Q47 What screening recommendations would you give this patient?
o Population-level screening (1)
o Lynch syndrome screening (2)
o Other (3) ________________________________________________
Q48 What screening recommendations would you give this patient’s first-degree relatives?
o Population-level screening (1)
o Earlier colonoscopy based on family history (2)
o Lynch syndrome screening (3)
o Other (4) ________________________________________________
Start of Block: Scenario 3
Q49 The following questions refer to the scenario below:
Ms. Davis is a 46-year old female recently diagnosed with uterine cancer. Tumor testing revealed loss of
staining in MSH2 and MSH6. The patient’s family history is below:

Q50 What would you perceive this patient’s chance of having Lynch syndrome to be?
o This patient absolutely has Lynch syndrome (1)
o It’s highly likely this patient has Lynch syndrome (2)
o It’s unlikely this patient has Lynch syndrome (3)
o This patient definitely does not have Lynch syndrome (4)
Q51 What would be your next step in evaluating this patient for Lynch syndrome?
o Germline testing to include MMR genes (1)
o Germline testing to include MMR genes with reflex to somatic MMR testing if negative (2)
o Concurrent germline testing to include MMR genes plus somatic MMR testing (3)
o No further evaluation (4)
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o

Other (5) ________________________________________________

Q52 Somatic MMR testing reveals a monoallelic somatic mutation in MSH2. Germline testing for MMR
genes was negative. Given this additional information, what do you perceive this patient’s chance of
having Lynch syndrome to be?
o This patient absolutely has Lynch syndrome (1)
o It’s highly likely this patient has Lynch syndrome (2)
o It’s unlikely this patient has Lynch syndrome (3)
o This patient definitely does not have Lynch syndrome (4)
Q53 What screening recommendations would you give this patient?
o Population-level screening (1)
o Lynch syndrome screening (2)
o Other (3) ________________________________________________
Q54 What screening recommendations would you give this patient’s first-degree relatives?
o

Population-level screening (1)

o

Earlier colonoscopy based on family history (2)

o

Lynch syndrome screening (3)

o

Other (4) ________________________________________________

Start of Block: Scenario 4
Q55 The following questions refer to the scenario below:
Mr. Roberts is a 62-year old male recently diagnosed with colorectal cancer. Tumor testing revealed a
loss of staining in MLH1 and PMS2. MLH1 promoter methylation and BRAF mutation analysis were
both negative. The patient’s family history is below:

Q56 What would you perceive this patient’s chance of having Lynch syndrome to be?
o This patient absolutely has Lynch syndrome (1)
o It’s highly likely this patient has Lynch syndrome (2)
o It’s unlikely this patient has Lynch syndrome (3)
o This patient definitely does not have Lynch syndrome (4)
Q57 What would be your next step in evaluating this patient for Lynch syndrome?
o Germline testing to include MMR genes (1)
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o
o
o
o

Germline testing to include MMR genes with reflex to somatic MMR testing if negative (2)
Concurrent germline testing to include MMR genes plus somatic MMR testing (3)
No further evaluation (4)
Other (5) ________________________________________________

Q58 Somatic MMR testing and germline testing for MMR genes were both negative. Given this
additional information, what do you perceive this patient’s chance of having Lynch syndrome to be?
o This patient absolutely has Lynch syndrome (1)
o It’s highly likely this patient has Lynch syndrome (2)
o It’s unlikely this patient has Lynch syndrome (3)
o This patient definitely does not have Lynch syndrome (4)
Q59 What screening recommendations would you give this patient?
o Population-level screening (1)
o Lynch syndrome screening (2)
o Other (3) ________________________________________________
Q60 What screening recommendations would you give this patient’s first-degree relatives?
o Population-level screening (1)
o Earlier colonoscopy based on family history (2)
o Lynch syndrome screening (3)
o Other (4) ________________________________________________
Start of Block: Conclusion
Q60 Would additional, more specific, national guidelines for ordering and/or the interpretation of MMR
somatic tumor testing be beneficial to you?
o Yes (1)
o Maybe (2)
o No (3)
o Unsure (4)
Q61 Do you have any additional comments that were not addressed by this survey?
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